Novel Therapeutic Strategies for Gastric Ulcer Healing and Antibiotic Resistance Management
DOI:
https://doi.org/10.64261/fr8j9y04Keywords:
Helicobacter pylori, Nanomedicine, Polymeric nanoparticles, Gastro retentive drug delivery systems, Mucoadhesive systems, Microbiome-targeted therapy.Abstract
The disease of gastric ulcers remains a significant source of health and socioeconomic burden in the globe despite modern techniques emerging in diagnosis, elimination of Helicobacter pylori, as well as acid-lowering medications. Mainstream therapy regimens such as proton pump inhibitors (PPIs), H2 receptor antagonists, antacids and antibiotic regimens are proving effective but are progressively limited due to increasing resistance in antibiotics, incomplete mucosal healing, elevated rates of recurrence and safety issues with long term acid suppression. Such restriction has prompted the innovative therapeutic mode of action of both the pathogenic and the shortcomings of conventional care. New nanomedicine systems like liposomal systems, polymeric nanoparticles, nano emulsions, and green-synthesized metallic nanoparticles are providing superior drug stability, targeted delivery, bio adhesion, and drug release; preclinical studies show these nanoparticles are having superior anti-inflammatory and antioxidant as well as anti-H. pylori effects, but still in early translational development. GRDSS Complementary gastro retentive drug delivery systems (GRDSS) which are: floating, swelling, mucoadhesive, super-porous hydrogel and high-density systems, all exhibit long gastric retention, high local drug concentration, and better eradication results than traditional preparations. New technologies in gene therapy, stem-cell delivery, growth-factor-based treatments, stimuli-responsive smart materials and precision-medicine devices, such as 3D-printed dosage forms and computerized health, are evidence of a paradigm shift with regards to customized and regenerative management of ulcers
References
1. Srivastav, Y., et al., Peptic ulcer disease (PUD), diagnosis, and current medication-based management options: schematic overview. Journal of Advances in Medical and Pharmaceutical Sciences, 2023. 25(11): p. 14-27.
2. Singh, S., et al., Overview of Peptic Ulcer Disease: Epidemiology, Causes, Pathophysiology, and Clinical Importance. Current Pharmaceutical Research, 2025: p. 222-230.
3. Sheranov, A.M., Types of Chronic Gastric and Duodenal Ulcer Disease, Complications, Incidence and Modern Methods of Examination. International Journal of Alternative and Contemporary Therapy, 2025. 3(2): p. 23-27.
4. Schulz, C., et al., Helicobacter pylori antibiotic resistance: a global challenge in search of solutions. Gut, 2025. 74(10): p. 1561-1570.
5. Razavi, Z.S., et al., Application of novel strategies in chronic wound management with focusing on pressure ulcers: new perspective. Archives of Dermatological Research, 2025. 317(1): p. 320.
6. Yuan, Y., et al., A new paradigm for drug discovery in the treatment of complex diseases: drug discovery and optimization. Chinese Medicine, 2025. 20(1): p. 40.
7. Erfan, I.A., et al., Gastric Ulcer: An Overview of Pathophysiology, Diagnosis, and Management. Records of Pharmaceutical and Biomedical Sciences, 2025. 9(1): p. 162-186.
8. Müller, A.L.E., Evaluation of the frequency and necessity of proton-pump-inhibitor therapy in geriatric patients. 2024, University of Split. School of Medicine.
9. Huang, T.-T., Y.-X. Cao, and L. Cao, Novel therapeutic regimens against Helicobacter pylori: An updated systematic review. Frontiers in Microbiology, 2024. 15: p. 1418129.
10. Wallace, J.L., Prostaglandins, NSAIDs, and gastric mucosal protection: why doesn't the stomach digest itself? Physiological reviews, 2008. 88(4): p. 1547-1565.
11. Porro, G.B., et al., Role of Helicobacter pylori in ulcer healing and recurrence of gastric and duodenal ulcers in longterm NSAID users. Response to omeprazole dual therapy. Gut, 1996. 39(1): p. 22-26.
12. Kasahun, G.G., G.T. Demoz, and D.M. Desta, Primary resistance pattern of Helicobacter pylori to antibiotics in adult population: a systematic review. Infection and drug resistance, 2020: p. 1567-1573.
13. Bilodeau, E.A. and R.V. Lalla, Recurrent oral ulceration: Etiology, classification, management, and diagnostic algorithm. Periodontology 2000, 2019. 80(1): p. 49-60.
14. Andrawes, M., et al., Proton Pump Inhibitors (PPIs)—An Evidence-Based Review of Indications, Efficacy, Harms, and Deprescribing. Medicina, 2025. 61(9): p. 1569.
15. Samreen, M., B. Jeevan, and H. Rahman, H2 Blockers and PPI: Review of Cases causing Adverse Drug Reactions. East African Scholars Journal of Medicine and Surgery, 2019. 1(1): p. 16-27.
16. Ching, C.-K. and S.-K. Lam, Antacids: indications and limitations. Drugs, 1994. 47(2): p. 305-317.
17. Lamsaouri, H., The role of the pharmacist in the pvevention of peptic ulcer disease and its complications. 2024.
18. Nautiyal, H., et al., Mechanism of action of drugs used in gastrointestinal diseases, in How Synthetic Drugs Work. 2023, Elsevier. p. 391-419.
19. Elbehiry, A., et al., Helicobacter pylori: Routes of Infection, Antimicrobial Resistance, and Alternative Therapies as a Means to Develop Infection Control. Diseases, 2024. 12(12): p. 311.
20. Garutti, M., et al., Nutritional management of oncological symptoms: a comprehensive review. Nutrients, 2023. 15(24): p. 5068.
21. Saha, M., et al., Nanoemulsion as a promising drug delivery strategy for effective eradication of Helicobacter pylori: current insights. Drug Delivery and Translational Research, 2025: p. 1-28.
22. Pande, S., Liposomes for drug delivery: review of vesicular composition, factors affecting drug release and drug loading in liposomes. Artificial Cells, Nanomedicine, and Biotechnology, 2023. 51(1): p. 428-440.
23. Idrees, H., et al., A review of biodegradable natural polymer-based nanoparticles for drug delivery applications. Nanomaterials, 2020. 10(10): p. 1970.
24. Chime, S., F. Kenechukwu, and A. Attama, Characterization and Applications in Drug Delivery. Application of nanotechnology in drug delivery, 2014: p. 77.
25. Gupta, A., et al., Treatment of H. pylori infection and gastric ulcer: Need for novel Pharmaceutical formulation. Heliyon, 2023. 9(10).
26. Albalawi, M. and S. Khateeb, Development of glycyrrhizic acid nanoparticles for modulating gastric ulcer healing: a comparative in vivo study targeting oxidative stress and inflammatory pathways. Antioxidants, 2025. 14(8): p. 990.
27. Spósito, L., et al., Nano-in-microparticles approach: Targeted gastric ulcer therapy using trans-resveratrol nanoparticles encapsulated in hyaluronic acid and alginate microparticles. International Journal of Biological Macromolecules, 2025. 305: p. 141010.
28. Attia, R.T., et al., Mucoadhesive chitosan-coated boswellic acids nanoparticles as promising gastroprotective nanoagents via modulation of the RAS/ERK signaling pathway. Discover Nano, 2025. 20(1): p. 1-19.
29. Zhang, S., et al., Green synthesis, biomedical effects, and future trends of Ag/ZnO bimetallic nanoparticles: An update. Nanotechnology Reviews, 2025. 14(1): p. 20250186.
30. Khan, N.U., et al., Bio-evaluations of sericin coated hesperidin nanoparticles for gastric ulcer management. Colloids Surf B Biointerfaces, 2024. 234: p. 113762.
31. Alamoudi, J.A., et al., Chitosan/hesperidin nanoparticles formulation: a promising approach against ethanol-induced gastric ulcers via Sirt1/FOXO1/PGC-1α/HO-1 pathway. Front Pharmacol, 2024. 15: p. 1433793.
32. Albalawi, M. and S. Khateeb, Development of Glycyrrhizic Acid Nanoparticles for Modulating Gastric Ulcer Healing: A Comparative In Vivo Study Targeting Oxidative Stress and Inflammatory Pathways. Antioxidants (Basel), 2025. 14(8).
33. Spósito, L., et al., Nano-in-microparticles approach: Targeted gastric ulcer therapy using trans-resveratrol nanoparticles encapsulated in hyaluronic acid and alginate microparticles. Int J Biol Macromol, 2025. 305(Pt 2): p. 141010.
34. Tan, S.L.J. and N. Billa, Improved bioavailability of poorly soluble drugs through gastrointestinal muco-adhesion of lipid nanoparticles. Pharmaceutics, 2021. 13(11): p. 1817.
35. Bahramikia, S. and R. Izadi, Plant-based green synthesis of nanoparticles as an effective and safe treatment for gastric ulcer. Inflammopharmacology, 2023. 31(6): p. 2843-2855.
36. Zheng, C., M. Li, and J. Ding, Challenges and opportunities of nanomedicines in clinical translation. Bio Integration, 2021. 2(2): p. 57.
37. Narmani, A., et al., Biomedical applications of PLGA nanoparticles in nanomedicine: advances in drug delivery systems and cancer therapy. Expert Opin Drug Deliv, 2023. 20(7): p. 937-954.
38. Xue, J., C. Blesso, and Y. Luo, A comprehensive review of nanoparticles for oral delivery in food: biological fate, evaluation models, and gut microbiota influences. Annual Review of Food Science and Technology, 2023. 14(1): p. 1-33.
39. Pippa, N., M. Gazouli, and S. Pispas, Recent advances and future perspectives in polymer-based nanovaccines. Vaccines, 2021. 9(6): p. 558.
40. Noori, M.M. and D.I. Ahmed, Floating Drug Delivery System: A Promising Approach for Gastroprotective Drug Delivery. Journal of Pharmacology and Drug Development, 2025. 3(2): p. 54-73.
41. Rump, A., et al., In Vitro and In Vivo Evaluation of Carbopol 71G NF-Based Mucoadhesive Minitablets as a Gastroretentive Dosage Form. Mol Pharm, 2023. 20(3): p. 1624-1630.
42. Subramanian, D.A., R. Langer, and G. Traverso, Mucus interaction to improve gastrointestinal retention and pharmacokinetics of orally administered nano-drug delivery systems. Journal of nanobiotechnology, 2022. 20(1): p. 362.
43. Uthumansha, U., et al., Optimization and In Vitro Characterization of Telmisartan Loaded Sodium Alginate Beads and Its In Vivo Efficacy Investigation in Hypertensive Induced Animal Model. Pharmaceutics, 2023. 15(2).
44. Kunkel, A.A. and K.J. McHugh, Injectable controlled‐release systems for the prevention and treatment of infectious diseases. Journal of Biomedical Materials Research Part A, 2024. 112(8): p. 1224-1240.
45. Blynskaya, E.V., et al., Polymeric Excipients in the Technology of Floating Drug Delivery Systems. Pharmaceutics, 2022. 14(12).
46. Kumar, V., et al., A recent update on gastro retentive drug delivery systems. GSC Biol. Pharm. Sci, 2024. 27: p. 125-144.
47. Ajalloueian, F., et al., High-yield fabrication of monodisperse multilayer nanofibrous microparticles for advanced oral drug delivery applications. Heliyon, 2024. 10(10).
48. Kawale, T., et al., Pharmacological innovations in the treatment of gastrointestinal disorders: a comprehensive review. International Journal of Scientific Research and Technology, 2024.
49. Abdul Rasool, B.K. and R. Sammour, DDSolver Software Application for Quantitative Analysis of In vitro Drug Release Behavior of the Gastroretentive Floating Tablets Combined with Radiological Study in Rabbits. Curr Drug Deliv, 2022. 19(9): p. 949-965.
50. Patel, S., M. Huang, and S. Miliara, Understanding treatment adherence in chronic diseases: challenges, consequences, and strategies for improvement. Journal of Clinical Medicine, 2025. 14(17): p. 6034.
51. Eberle, V.A., et al., In silico and in vitro methods to optimize the performance of experimental gastroretentive floating mini-tablets. Drug development and industrial pharmacy, 2016. 42(5): p. 808-817.
52. Maddiboyina, B., et al., Formulation and evaluation of gastro-retentive floating bilayer tablet for the treatment of hypertension. Heliyon, 2020. 6(11).
53. Turac, I.-R., et al., Expanding the manufacturing approaches for gastroretentive drug delivery systems with 3D printing technology. Pharmaceutics, 2024. 16(6): p. 790.
54. Waqar, M.A., et al., Advanced polymers and recent advancements on gastroretentive drug delivery system; a comprehensive review. Journal of drug targeting, 2024. 32(6): p. 655-671.
55. Nser, S.M., A.D.H. Al-Shohani, and A. Abuawad, Effect of using high molecular weight crosslinker on the physical properties of super porous hydrogel composite. Al Mustansiriyah Journal of Pharmaceutical Sciences, 2023. 23(4): p. 355-366.
56. Earl, E.E., High-density biocompatible hydrogels for in-vivo gastric acid relocation. 2021, University of British Columbia.
57. Pacyga, K., A. Tabiś, and P. Pacyga, Medicinal Plants for a Healthy Gut Microbiome: Scientific Insights into Modern Herbal Applications. International Journal of Molecular Sciences, 2025. 26(22): p. 10875.
58. Takeuchi, K., Pathogenesis of NSAID-induced gastric damage: importance of cyclooxygenase inhibition and gastric hypermotility. World journal of gastroenterology: WJG, 2012. 18(18): p. 2147.
59. Koga, Y., Microbiota in the stomach and application of probiotics to gastroduodenal diseases. World J Gastroenterol, 2022. 28(47): p. 6702-6715.
60. Lai, X., et al., Symbiotic bacteria-mediated imbalance and repair of immune homeostasis: exploring novel mechanisms of microbiome-host interactions in atopic dermatitis. Frontiers in immunology, 2025. 16: p. 1649857.
61. Li, J., et al., Dysbiosis of gut microbiota is associated with pathogenesis of peptic ulcer diseases through inflammatory proteins: A Mendelian randomization study. Medicine (Baltimore), 2024. 103(39): p. e39814.
62. Jin, L.X., et al., Helicobacter pylori infection alters gastric microbiota structure and biological functions in patients with gastric ulcer or duodenal ulcer. World J Gastroenterol, 2024. 30(24): p. 3076-3085.
63. Huangfu, L.X., et al., Irisin attenuates inflammation in a mouse model of ulcerative colitis by altering the intestinal microbiota. Experimental and Therapeutic Medicine, 2021. 22(6): p. 1433.
64. Bădăluță, V.A., et al., Probiotics in wound healing. International Journal of Molecular Sciences, 2024. 25(11): p. 5723.
65. Saghir, S.A.M. and F.S. Al Suede, Synergistic Efficacy and Mechanism of Probiotics and Prebiotics in Enhancing Health Impact. Microbial Bioactives, 2024. 7(1): p. 1-11.
66. Ball, P., et al., Antibiotic therapy of community respiratory tract infections: strategies for optimal outcomes and minimized resistance emergence. Journal of antimicrobial chemotherapy, 2002. 49(1): p. 31-40.
67. Saxena, A., A.K. Mukhopadhyay, and S.P. Nandi, Helicobacter pylori: Perturbation and restoration of gut microbiome. Journal of biosciences, 2020. 45(1): p. 110.
68. Cusumano, G., et al., The Impact of Antibiotic Therapy on Intestinal Microbiota: Dysbiosis, Antibiotic Resistance, and Restoration Strategies. Antibiotics, 2025. 14(4): p. 371.
69. Schupack, D.A., et al., The promise of the gut microbiome as part of individualized treatment strategies. Nature reviews Gastroenterology & hepatology, 2022. 19(1): p. 7-25.
70. Wilson, B. and K. Whelan, Prebiotic inulin‐type fructans and galacto‐oligosaccharides: definition, specificity, function, and application in gastrointestinal disorders. Journal of gastroenterology and hepatology, 2017. 32: p. 64-68.
71. Yoo, S., et al., The role of prebiotics in modulating gut microbiota: implications for human health. International Journal of Molecular Sciences, 2024. 25(9): p. 4834.
72. Al-Habsi, N., et al., Health benefits of prebiotics, probiotics, synbiotics, and postbiotics. Nutrients, 2024. 16(22): p. 3955.
73. Mayorgas, A., I. Dotti, and A. Salas, Microbial metabolites, postbiotics, and intestinal epithelial function. Molecular nutrition & food research, 2021. 65(5): p. 2000188.
74. Lim, E.C.N. and C.E.D. Lim, Microbiome-Targeted Therapies in Gastrointestinal Diseases: Clinical Evidence and Emerging Innovations. Acta Microbiologica Hellenica, 2025. 70(3): p. 36.
75. Xia, Y., et al., Gut microbiome and microbial metabolites in NAFLD and after bariatric surgery: Correlation and causality. Frontiers in Microbiology, 2022. 13: p. 1003755.
76. Dudhat, K., Nanotechnology-driven approaches for targeted rectal microbiome modulation in gastrointestinal disorders. Current Proteomics, 2025.
77. Kwang, G.D., Biocompatible floatable device for controlled release applications. 2023.
78. Ikumapayi, O.M. and O.T. Laseinde, Nanomanufacturing in the 21st Century: A Review of Advancements, Applications and Future Prospects. Journal Européen des Systèmes Automatisés, 2024. 57(4).
79. Rangaraj, N., et al., Fast-fed variability: insights into drug delivery, molecular manifestations, and regulatory aspects. Pharmaceutics, 2022. 14(9): p. 1807.
80. Prajapati, C., et al., Challenges and Future Perspectives in Microbiota-Based Precision Medicine: Standardization of Profiling Methods, Ethical Considerations and the Potential for Pre-emptive Healthcare, in Microbiota Profiling for Precision Medicine: Biomarker-Targeted Drug Delivery Strategies. 2025, Springer. p. 435-460.
81. Hofer, S., et al., Immunotoxicity of nanomaterials in health and disease: Current challenges and emerging approaches for identifying immune modifiers in susceptible populations. Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology, 2022. 14(6): p. e1804.
82. Chu, J.N. and G. Traverso, Foundations of gastrointestinal-based drug delivery and future developments. Nature Reviews Gastroenterology & Hepatology, 2022. 19(4): p. 219-238.
83. Ezike, T.C., et al., Advances in drug delivery systems, challenges and future directions. Heliyon, 2023. 9(6).
84. Rajput, A., Investigation of mechanisms and clinical implications of drug interactions: a review. Trends Pharm Nanotechnol, 2024. 6(1): p. 41-54.
85. Kardani, S.L., Nanocarrier-based formulations: regulatory challenges, ethical and safety considerations in pharmaceuticals. Asian Journal of Pharmaceutics (AJP), 2024. 18(02).
86. Páez, A., et al., Beyond the RCT: when are randomized trials unnecessary for new therapeutic devices, and what should we do instead? Annals of Surgery, 2022. 275(2): p. 324-331.
87. Voykelatos, G., Good Manufacturing Practices (GMPs) and process validation in the pharmaceutical industry: an in depth analysis. 2022, Πανεπιστήμιο Πειραιώς.
88. Silva, V., J. Joaquim, and C. Matos, Post-marketing regulatory actions in Portugal—A retrospective analysis between 2013 and 2023. International Journal of Risk & Safety in Medicine, 2025. 36(1): p. 49-56.
89. Reid, M., How the incomplete medicalization of cannabis shapes patient experiences. Sociological Focus, 2023. 56(1): p. 97-114.
90. Zheng, G., et al., Therapeutic applications and potential biological barriers of nano-delivery systems in common gastrointestinal disorders: a comprehensive review. Advanced Composites and Hybrid Materials, 2025. 8(2): p. 1-22.
91. Clemente-Suárez, V.J., et al., Biomimetic Strategies for Nutraceutical Delivery: Advances in Bionanomedicine for Enhanced Nutritional Health. Biomimetics, 2025. 10(7): p. 426.
92. Patel, R., GMP Facility Design: Ensuring Compliance and Operational Efficiency in Biomedical and Pharmaceutical Industries.
93. Pore, A.V., S.K. Bais, and M.M. Kamble, Pharmacovigilance in clinical research. International Journal of Pharmacy and Herbal Technology, 2024. 2(1): p. 759-775.
Downloads
Published
Issue
Section
Categories
License
Copyright (c) 2026 Pan-African Journal of Health and Psychological Sciences
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
All articles published in the Pan-African Journal of Health and Psychological Sciences (PAJHPS) are open access and distributed under the terms of the Creative Commons Attribution 4.0 International License (CC BY 4.0).
Under this license:
-
Authors retain copyright and grant the journal the right of first publication.
-
The work may be shared, copied, redistributed, and adapted for any purpose, even commercially.
-
Appropriate credit must be given to the original author(s) and the journal, along with a link to the license.
-
Users must indicate if changes were made.
-
There are no restrictions on reuse, provided the original work is properly cited.
Citation:
Authors and users must cite the original work in the following manner:
Author(s). (Year). Title of the article. Pan-African Journal of Health and Psychological Sciences, Volume(Issue), page range. https://doi.org/xx.xxxx/pajhps.vXnY.xxx
Copyright Statement:
Authors grant PAJHPS a non-exclusive license to publish the work and identify itself as the original publisher. Authors may enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version (e.g., post it to a repository or publish it in a book), with acknowledgment of its initial publication in this journal.
